Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Fu, Jiao ^a   Lv, Hongjun ^a   Guan, Haixia ^b   Ma, Xiaoying ^a   Ji, Meiju ^a   He, Nongyue ^c   Shi, Bingyin ^a   Hou, Peng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c SOUTHEAST UNIVERSITY   (China)

Author keywords

DNA methylation; Metallothionein 1G (MT1G); PI3K Akt pathway; Rb E2F pathway; Thyroid cancer

Indexed keywords

MESSENGER RNA; METALLOTHIONEIN; METALLOTHIONEIN 1G; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL ASSAY; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; DOWN REGULATION; ENZYME PHOSPHORYLATION; EPIGENETICS; FEMALE; GENE SILENCING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIMARY TUMOR; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LYMPHATIC METASTASIS; MALE; METALLOTHIONEIN; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84885010248     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-462     Document Type: Article

References (46)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295:2164-2167. 10.1001/jama.295.18.2164, 16684987.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
3. Sherman SI. Thyroid carcinoma. Lancet 2003, 361:501-511. 10.1016/S0140-6736(03)12488-9, 12583960.
4. Cornett WR, Sharma AK, Day TA, Richardson MS, Hoda RS, van Heerden JA, Fernandes JK. Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 2007, 9:152-158. 10.1007/s11912-007-0014-3, 17288883.
5. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011, 7:569-580. 10.1038/nrendo.2011.142, 21878896.
6. Russo D, Damante G, Puxeddu E, Durante C, Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol 2011, 46:R73-R81. 10.1530/JME-10-0150, 21325372.
7. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007, 13:1161-1170. 10.1158/1078-0432.CCR-06-1125, 17317825.
8. Shinohara M, Chung YJ, Saji M, Ringel MD. AKT in thyroid tumorigenesis and progression. Endocrinology 2007, 148:942-947.
9. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
10. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007, 148:948-953.
11. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011, 11:726-734. 10.1038/nrc3130, 3307543, 21941284.
12. Issa JP. DNA methylation as a clinical marker in oncology. J Clin Oncol 2012, 30:2566-2568. 10.1200/JCO.2012.42.1016, 22564986.
13. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012, 13:679-692. 10.1038/nrg3270, 22945394.
14. West AK, Stallings R, Hildebrand CE, Chiu R, Karin M, Richards RI. Human metallothionein genes: structure of the functional locus at 16q13. Genomics 1990, 8:513-518. 10.1016/0888-7543(90)90038-V, 2286373.
15. Romero-Isart N, Vasak M. Advances in the structure and chemistry of metallothioneins. J Inorg Biochem 2002, 88:388-396. 10.1016/S0162-0134(01)00347-6, 11897355.
16. Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: the multipurpose protein. Cell Mol Life Sci 2002, 59:627-647. 10.1007/s00018-002-8454-2, 12022471.
17. Vasák M. Advances in metallothionein structure and functions. J Trace Elem Med Biol 2005, 19:13-17. 10.1016/j.jtemb.2005.03.003, 16240666.
18. Nielsen AE, Bohr A, Penkowa M. The Balance between Life and Death of Cells: Roles of Metallothioneins. Biomark Insights 2007, 1:99-111. 2716779, 19690641.
19. Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellularcarcinoma using a novel method of double combination array analysis. Int J Oncol 2009, 35:477-483.
20. Arriaga JM, Levy EM, Bravo AI, Bayo SM, Amat M, Aris M, Hannois A, Bruno L, Roberti MP, Loria FS, Pairola A, Huertas E, Mordoh J, Bianchini M. Metallothionein expression in colorectal cancer: relevance of different isoforms for tumorprogression and patient survival. Hum Pathol 2012, 43:197-208. 10.1016/j.humpath.2011.04.015, 21820154.
21. Henrique R, Jerónimo C, Hoque MO, Nomoto S, Carvalho AL, Costa VL, Oliveira J, Teixeira MR, Lopes C, Sidransky D. MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1274-1278. 10.1158/1055-9965.EPI-04-0659, 15894685.
22. Huang Y, de la Chapelle A, Pellegata NS. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 2003, 104:735-744. 10.1002/ijc.11006, 12640681.
23. Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, Cleris L, Formelli F, Pilotti S, Pierotti MA, Greco A. Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Invest 2008, 88:474-481. 10.1038/labinvest.2008.17, 18332874.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
25. Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 2008, 113:2440-2447. 10.1002/cncr.23869, 18831514.
26. Liu D, Hou P, Liu Z, Wu G, Xing M. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009, 69:7311-7319. 10.1158/0008-5472.CAN-09-1077, 2756336, 19706758.
27. Saraste A. Morphologic criteria and detection of apoptosis. Herz 1999, 24:189-195. 10.1007/BF03044961, 10412642.
28. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001, 98:11598-11603. 10.1073/pnas.181181198, 58775, 11504915.
29. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001, 3:973-982. 10.1038/ncb1101-973, 11715018.
30. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N, Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002, 277:21843-21850. 10.1074/jbc.M109745200, 11923280.
31. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501. 10.1038/nrc839, 12094235.
32. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005, 24:7443-7454. 10.1038/sj.onc.1209091, 16288291.
33. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001, 10:699-703. 10.1093/hmg/10.7.699, 11257102.
34. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009, 9:738-748. 10.1038/nrc2718, 19776743.
35. Brzezianska E, Pastuszak-Lewandoska D. A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm. Front Biosci 2011, 16:422-439.
36. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012, 16(Suppl 2):S17-S27.
37. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995, 55:5187-5190.
38. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004, 6:443-450. 10.1038/ncb1123, 15077116.
39. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001, 29:688. 10.1042/BST0290688, 11709055.
40. Levav-Cohen Y, Haupt S, Haupt Y. Mdm2 in growth signaling and cancer. Growth Factors 2005, 23:183-192. 10.1080/08977190500196218, 16243710.
41. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003, 1:1001-1008.
42. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000, 2:76-83. 10.1038/35000025, 10655586.
43. Alves CC, Carneiro F, Hoefler H, Becker KF. Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci 2009, 14:3035-3050.
44. Puisieux A, Valsesia-Wittmann S, Ansieau S. A twist for survival and cancer progression. Br J Cancer 2006, 94:13-17. 10.1038/sj.bjc.6602876, 2361066, 16306876.
45. Yang JY, Zong CS, Xia W, Wei Y, Ali-Seyed M, Li Z, Broglio K, Berry DA, Hung MC. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol 2006, 26:7269-7282. 10.1128/MCB.00172-06, 1592879, 16980628.
46. Kim TR, Lee HM, Lee SY, Kim EJ, Kim KC, Paik SG, Cho EW, Kim IG. SM22α-induced activation of p16INK4a/retinoblastoma pathway promotes cellular senescence caused by a subclinical dose of γ-radiation and doxorubicin in HepG2 cells. Biochem Biophys Res Commun 2010, 400:100-105. 10.1016/j.bbrc.2010.08.018, 20705054.